Select a Region
North America

Browsing Archive: Multiple SclerosisMultiple Sclerosis | EVERSANA

EVERSANA
Posted on 4 月 29, 20254/29/25

Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons

EVERSANA
Posted on 3 月 8, 20253/8/25

Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies

EVERSANA
Posted on 2 月 1, 20232/1/23

Efficacy classification of modern therapies in multiple sclerosis

EVERSANA
Posted on 2 月 1, 20232/1/23

Network Meta-analysis of Disease-modifying Therapies for Relapsing Multiple Sclerosis Based on Confirmed Disability Progression: Investigating the Influence of Cross-trial Differences in Endpoint Definition

EVERSANA
Posted on 2 月 1, 20232/1/23

Relapse Reduction by Disease-modifying Therapies for Relapsing Multiple Sclerosis: A Network Meta-analysis

EVERSANA
Posted on 2 月 1, 20232/1/23

Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review

EVERSANA
Posted on 2 月 1, 20232/1/23

Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses

EVERSANA
Posted on 2 月 1, 20232/1/23

Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis

EVERSANA
Posted on 2 月 1, 20232/1/23

A systematic review and network meta‐analysis comparing ofatumumab with other disease‐modifying therapies available in Japan for the treatment of patients with relapsing multiple sclerosis

Multiple Sclerosis